The review discusses fifty eight peptides in several clinical phases, indicating a strong pipeline of peptide therapies focusing on PPIs. Clinical trials and preclinical studies are highlighted, demonstrating the efficacy of peptide vaccines in inducing an immune response, with the likely to boost survival costs for HCC people. A number https://edwinr986swv7.blogaritma.com/profile